Nov. 16, 2007
Doing good could help drug-development companies do well.
Under legislation signed into law seven weeks ago, a company that develops and wins approval of a drug to treat a neglected disease can snag a voucher giving it priority review for almost any future drug -- for a neglected disease or not.
That could give drug-development companies focused on diseases ranging from tuberculosis to human African trypanosomiasis an asset that some experts have valued at $300 million each.
Friday, October 09, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment